Abstract Library

#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,

Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,

#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)

Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,

Keywords: prognostic, biomarker, PRRT, LuTate,

#1636 Preoperative Blood Neutrophil-To-Lymphocyte Ratio-Based Nomogram Predicts Lymph Node Metastasis in Patients of Resectable Pancreatic Neuroendocrine Tumors

Introduction: Neutrophil-to-lymphocyte ratio(NLR) is one of the systemic inflammation markers, which has prognostic values in many types of tumor. However, hardly no research has reported the relationship between NLR and pancreatic neuroendocrine tumors(panNETs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tong Z

Authors: Tong Z, Liu L, Zheng Y, Jiang W, Zhao P,

Keywords: pancreatic neuroendocrine tumors, NLR, lymph node metastasis,